{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:07:06Z","timestamp":1790957226160,"version":"4.1.0"},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG083189"],"award-info":[{"award-number":["R01AG083189"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>Three treatments for Alzheimer's disease have been approved in the United States. Data are lacking on the characteristics of the initial treatment recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We identified treatment recipients in the full Medicare fee\u2010for\u2010service data for 2021 to 2023. We compared their age, sex, race\/ethnicity, dual eligibility, comorbidities, and median household income and educational attainment in their residence's ZIP Code Tabulation Area (ZCTA) to those of the overall Medicare population aged 65+.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Treated patients were more likely to be non\u2010Hispanic White (89% vs 82%) and less likely to be dually eligible (1% vs 8.8%). Average median household income ($97,136 vs $84,449) and proportion of residents with at least a bachelor's degree (41% vs 31%) were higher in treated patients\u2019 ZCTAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>The first patients receiving amyloid\u2010targeting treatment represent a more privileged subset. While needing to be confirmed with more data, these results point to the need for efforts to make access more equitable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Little is known about the initial 924 patients receiving amyloid\u2010targeting treatments in the United States from 2021 to 2023.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>They were more likely to be White and less likely to be dually eligible than the Medicare population.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>They resided in wealthier and more highly educated areas.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Comorbidity burden was similar to that observed in clinical trials.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Those initial results point to the need to improve equitable access to treatment.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/alz.70054","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T22:42:40Z","timestamp":1741732960000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Demographic and clinical characteristics of initial patients receiving amyloid\u2010targeting treatments in the United States after regulatory approval"],"prefix":"10.1002","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4666-9132","authenticated-orcid":false,"given":"Soeren","family":"Mattke","sequence":"first","affiliation":[{"name":"The USC Brain Health Observatory, USC Dornsife  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selena","family":"Yue","sequence":"additional","affiliation":[{"name":"The USC Brain Health Observatory, USC Dornsife  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Becker","sequence":"additional","affiliation":[{"name":"The USC Brain Health Observatory, USC Dornsife  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"The USC Brain Health Observatory, USC Dornsife  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"As sales climb Biogen \u2018convinced\u2019 the worst is over for Leqembi. BiopharmaDive;2024.https:\/\/www.biopharmadive.com\/news\/biogen\u2010earnings\u2010leqembi\u2010sales\u2010lilly\u2010kisunla\u2010alzheimers\/723023\/"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12470"},{"key":"e_1_2_8_4_1","unstructured":"Alzheimer's drug Leqembi promises to give patients more time but they face a long road to treatment. CNBC;2024.https:\/\/www.cnbc.com\/2024\/09\/08\/leqembi\u2010alzheimers\u2010patients\u2010biogen\u2010eisai.html#:~:text=Leqembi%2C%20an%20Alzheimer%27s%20drug%20from associated%20with%20taking%20the%20drug"},{"key":"e_1_2_8_5_1","unstructured":"The real costs of the new Alzheimer's drug Leqembi \u2014 and why taxpayers will foot much of the bill. CBS News;2023.https:\/\/www.cbsnews.com\/news\/alzheimers\u2010drug\u2010leqembi\u2010cost\u2010patients\u2010taxpayers\/"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit003"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit599"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12684"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0033354918772059"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)01296\u20100"},{"key":"e_1_2_8_11_1","unstructured":"Median household income in the past 12 months (in 2021 inflation\u2010adjusted dollars) American Community Survey 5\u2010Year Estimates Subject Tables Table B19013. U.S. Census Bureau. December 1 2024.https:\/\/data.census.gov\/table?q=B19013&g=010XX00US$8600000>"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.61"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666\u20107568(23)00211\u20108"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.3543"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.159"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.70054","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.70054","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.70054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:20:34Z","timestamp":1789554034000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.70054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/alz.70054"],"URL":"https:\/\/doi.org\/10.1002\/alz.70054","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70054"}}